14 results about "Artery dissection" patented technology

The invention relates to the technical field of molecular biology and medicine, and particularly discloses application of WWP1 in preparation of a medicine for preventing and / or treating aortic dissection, and relates to application of WWP1 in prevention and treatment of aortic dissection. Molecular biology experiment detection of the expression level of the WWP1 in aortic dissection aortic tissue and the expression level of smooth muscle cell contraction and secretion phenotype marker genes proves that the expression level of the WWP1 in an aortic dissection aortic tissue sample is obviously higher than that of a control aortic tissue; and overexpression of the WWP1 in an animal model significantly reduces the morbidity of the aortic dissection and improves the contraction phenotype of the aortic smooth muscle, i.e., the protectiveness of the WWP1 in the morbidity process of the aortic dissection is improved. Based on the research result, the WWP1 can be used as a drug target for screening, preventing and treating the aortic dissection.

This invention discloses a targeted nanocarrier for the diagnosis and treatment of arterial dissection and its preparation method. The targeted nanocarrier is composed of a macromolecular prodrug self-assembly constructed by covalently linking the NLRP3 inhibitor CY-09 and oxidized fucoidan through phenylboronic acid ester bonds and imine bonds, using iodine contrast agent ICA as a connecting bridge. The targeted nanocarrier prepared by this invention possesses good stability, drug release characteristics, excellent dissection targeting, and dual responsiveness to reactive oxygen species and acidic microenvironments, demonstrating significant imaging diagnostic and therapeutic effects on arterial dissection.

The invention discloses application of KAT7 as a target spot in treatment of aortic aneurysm and dissection. According to the application, an AngII-induced aortic aneurysm mouse model is applied, the treatment effect of the KAT7 inhibitor WM3835 on aortic aneurysm / dissection is detected through mouse survival rate, aortic aneurysm occurrence rate, aorta width, blood vessel staining and WB staining indexes, and the WM3835 can slow down the occurrence and progress of aortic aneurysm, reduce the occurrence of aortic dissection and improve the survival rate of aortic aneurysm / dissection, so that the KAT7 inhibitor WM3835 can be used for treating aortic aneurysm / dissection. And a new target and a new medicine are provided for clinically treating aorta and dissection of aortic aneurysm. The KAT7 inhibitor WM3835 provided by the invention is a brand new drug treatment means for treating aortic aneurysm and dissection, is an important supplement for operative treatment of aortic aneurysm / dissection, and has important clinical significance.

The application provides an aortic dissection postoperative cardiopulmonary function rehabilitation device, and belongs to the technical field of cardiopulmonary rehabilitation. The aortic dissection postoperative cardiopulmonary function rehabilitation device comprises a fixing structure and a clamping structure, the fixing structure comprises a first gasket, a second gasket, a U-shaped frame, a fixing assembly, a rectangular shell, an adjusting assembly, an arc-shaped clamping plate and two connecting belts, the first gasket is rotationally connected with the second gasket, the U-shaped frame is slidingly connected with the first gasket, the fixing assembly is connected with the U-shaped frame, and the rectangular shell is connected with the fixing assembly. In the application, the aortic dissection postoperative cardiopulmonary function rehabilitation device can conveniently avoid foot deviation during rehabilitation training, improve the training effect, and conveniently adjust the position of the U-shaped frame according to the height of a user, thereby improving the practicability of the device.

This invention provides a method and system for predicting the risk of aortic remodeling after aortic dissection, comprising the following steps: receiving CTA images of the patient's chest and abdomen at multiple time points, such as preoperative and short or mid-operative postoperatively, and obtaining aortic segmentation results based on the CTA images; obtaining the displacement field of each voxel point between the two time points based on the aortic segmentation results, and obtaining vascular deformation mapping results based on the displacement field; extracting multi-dimensional features from the three-dimensional aortic segmentation model and the vascular deformation mapping results respectively; and predicting the risk of adverse aortic remodeling after surgery based on the multi-dimensional features. The beneficial effects of this invention are: by comprehensively utilizing multi-dimensional, dynamic, and static features, the prediction model constructed by this invention theoretically has higher discrimination and calibration than existing single-index models. Therefore, this invention can detect early, local abnormal deformations that cannot be detected by traditional diameter measurement, significantly advancing the risk identification time point.

Use of a serine / arginine-rich splicing factor 1 (SRSF1) as a therapeutic target for aortic dissection is provided, which belonging to the technical field of biomedicine. The SRSF1 can be used as a target to screen a drug for preventing and / or treating aortic dissection. SRSF1 expression is upregulated in both β-aminopropionitrile (BAPN)-induced aortic dissection model mice and aortic dissection patients. Mice with SRSF1 knockdown in vascular smooth muscle cells (VSMCs) are less susceptible to aortic dissection and elastic fiber degradation induced by BAPN. Mice with high expression of SRSF1 in VSMCs are more susceptible to aortic dissection and elastic fiber degradation induced by BAPN. Mechanistically, the SRSF1 can regulate the inflammatory phenotype of vascular smooth muscle and promote the degradation of vascular extracellular matrix. Knocking down the SRSF1 may improve the above phenomenon, thereby providing a new target for the treatment of aortic dissection.

The application provides an aortic dissection rupture sealing device, which comprises an anchoring part, a hollow flow channel, and an intima around the rupture, so as to prevent the fluid communication between the true lumen of the aorta and the false lumen formed at the rupture; a stent, which is adjustably coupled to the anchoring part, has a connecting end and a free end, and at least the free end of the stent is located in a branch blood vessel; and the stent has a hollow structure in communication with the hollow flow channel and is supported in the branch blood vessel to communicate the true lumen and the branch blood vessel. The above scheme can avoid the continuous expansion of the false lumen caused by the incomplete sealing of the rupture and residual shunt, and at the same time, the blood supply of the blood vessel channel is retained to ensure the stability of the blood supply of the branch blood vessel, which is beneficial to meet the blood supply demand of the internal organs, spinal cord and the like supplied by the branch blood vessel.

The invention discloses application of terazosin in preparation of drugs or health care products for preventing and / or treating aortic dissection, and relates to the technical field of medicines. Animal test and clinical research are carried out on the current clinical common drug terazosin, and the result shows that the small dose of terazosin can effectively prevent and treat the aortic dissection, so that important technical support is provided for early treatment or prevention of aortic related diseases. Experimental and clinical research results also prove that the terazosin with the dosage of 0.5 mg has a good effect in the aspects of improving the vascular elasticity and reducing the vascular pulse wave conduction velocity, the dosage can be greatly reduced, the medication cost can be saved, and the medical burden of a patient can be relieved. Meanwhile, due to the fact that the dosage of terazosin used in the human body is extremely low, adverse side effects related to terazosin are basically eradicated.

An explainable artificial intelligence system for early prediction of missed severe diagnoses in intensive care unit patients is provided. The system comprises a data processing module configured to receive and process electronic health record data including patient demographics, vital signs, laboratory results, and diagnostic codes. A machine learning module with ensemble, deep learning, and large language models analyzes processed data to predict likelihood of severe diagnoses including acute myocardial infarction, acute pulmonary embolism, bacterial pneumonia, aortic dissection, meningitis, spinal abscess, bacterial endocarditis, and arterial thromboembolism. An explainability module generates feature importance rankings and provides interpretable explanations for predictions.

This invention discloses a method and system for predicting in-hospital mortality risk in patients undergoing acute type A aortic dissection surgery based on interpretable machine learning. The method includes: collecting clinical data from patients undergoing acute type A aortic dissection surgery and constructing an original feature dataset; evaluating the feature importance of each feature in the original feature dataset to obtain a score for each feature, and filtering based on the scores to obtain a core feature dataset; inputting the core feature dataset corresponding to the target patient into a pre-trained in-hospital mortality risk prediction model, and outputting the predicted in-hospital mortality probability of the target patient; calculating the feature contribution corresponding to the predicted in-hospital mortality probability, and generating an interpretable result for the mortality risk prediction of the target patient. The technical solution of this invention can reduce model complexity, improve model generalization ability, and improve prediction accuracy and interpretability.

The invention belongs to the technical field of biological pharmacy, and provides an application of an HMGB2 inhibitor in preparation of a medicine for treating aortic dissection, and the application is that the HMGB2 inhibitor is applied to preparation of the medicine for treating aortic dissection. An aortic dissection model is established through animal experiments, and the treatment effect of the HMGB2 inhibitor is evaluated; results show that the HMGB2 inhibitor can inhibit development of the aortic dissection by improving the degree of vascular injury, blocking nucleation and secretion of HMGB2 cells, delaying the aging process of VSMCs and reducing HMGB2-mediated inflammation amplification effect and matrix degradation to achieve the purpose of treating the aortic dissection.

The invention discloses a biomarker for predicting the onset risk of aortic dissection, a kit and application. The invention provides application of a reagent for detecting the SERPINE1 level of peripheral blood in preparation of products for aortic dissection attack risk prediction, early screening, diagnosis or curative effect monitoring. The marker and the related detection kit can be used for predicting the occurrence risk of the aortic dissection, and are not limited to diagnosis of the occurred dissection; the method is suitable for screening and dynamic follow-up visit of high-risk groups; the operation is simple and convenient, and a detection sample can be obtained through peripheral blood; the aortic wall pathological remodeling and fibrinolytic / matrix stability change can be reflected. Clinical sample verification shows that the method for predicting the onset risk of the aortic dissection through the SERPINE1 level of the peripheral blood has relatively high sensitivity and specificity, and relatively high clinical application value and application prospect are shown.

The present invention provides a pharmaceutical composition containing ticagrelor for use in reducing or preventing thromboembolic events before and / or during and / or after neurovascular arterial procedures in a patient requiring the use of the pharmaceutical composition containing ticagrelor, comprising administering an effective amount of the pharmaceutical composition containing ticagrelor to a patient, wherein the pharmaceutical composition is an aqueous solution containing a solubilizing agent for ticagrelor and the pharmaceutical composition is administered intravenously; wherein the patient suffers from a cerebral aneurysm, cerebral arteriosclerosis, cervical arteriosclerosis, neurovascular carotid dissection or carotid dissection.

The application belongs to the technical field of disease diagnosis, and particularly relates to the use of CX3CL1 as a biomarker of acute type A aortic dissection. The application finds that CX3CL1 is a key inflammatory mediator of acute type A aortic dissection, and its plasma level is significantly positively correlated with neutrophil infiltration, IL-6, IL-8, IL-10, D-dimer and NT-proBNP. It is proved by characteristic curve analysis that there is a significant correlation between the CX3CL1 level and the severity of ATAAD. By evaluating the expression level of CX3CL1 protein in peripheral blood of a subject, an evaluation result related to the risk of suffering from acute type A aortic dissection is generated, non-invasive, fast and low-cost detection can be realized, and the problem that patients with renal dysfunction or contrast agent allergy cannot use CT angiography for diagnosis is solved.